THE TAPE
CRSP · Biotechnology · $3.9B

CRISPR Therapeutics AG

$40.37▼ −4.43%
Last close
Relative strength
14RS
of 99, against every stock▼ -10 on the month
Falling back
Unconfirmed
−32.3%
six months against Biotechnology
52-week range
−36.4%
from the high
$39.83$63.45
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +1325% on a year ago
Why it is on no screen

CRSP is off the screens on 2 checks.

A base has formed17.6 weeks, from 44.12 to 61.76.
Long enough to count17.6 weeks against 3 needed.
Shallow enough28.6% deep against 35% allowed.
Close to its pivot-34.6% from the pivot; listed down to -20%.
Relative strengthRS 14 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$48.21
+19.4% · tested 5× · last 7 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

CRISPR Therapeutics AG is not on any of the screens right now. Its relative strength rating is 14, and it sits in Biotechnology.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-20.3%
Three months against its industry
-18.7%
Six months against its industry
-32.3%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 5.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$25.2M
+1325.1% year on year
Operating margin
-2114.8%
Net margin
-1812.1%
Free cash flow
$-376.7M
-9.7% of market cap
Price to sales
155.1×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 2
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$12.7M
+24.4% QoQ · +1325.1% YoY
Gross margin
—
Net income
−$111.4M
Loss
Free cash flow
−$90.1M
Burning · 2q runway

What the numbers say

  • Good: Revenue +1325.1% year over year, +24.4% on the quarter
  • Weak: Net loss $111M, wider than $91M last quarter
  • Weak: Burning cash: operating cash flow -$90M, free cash flow -$90M, worse than -$84M last quarter · 2 quarters of cash at this burn
  • Weak: Growth externally funded: capex $414K against operating cash flow -$90M; share count +6.0% in a year
  • Weak: Net debt $395M · cash $192M
Revenue by quarter
Free cash flow
Net income
shares +6.0% in a year · net debt $394.9M

What is not obvious

  • Weak: Stock compensation $18M added back against negative operating cash flow
  • Weak: Interest $3M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $111M, wider than $91M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
GappedTape · 2026-11-13
-6.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-11
below 20d & 50d on 2.8x volume at 45.15
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-11
-9.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-11
5.4 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-06
-6.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings comingEvent · 2026-11-03
reports 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Reported resultsFiling · 2026-11-03
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-10-31
-5.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy4
Buy9
Hold10
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
CRISPR Therapeutics AG (CRSP) — The Tape